Mindfulness‑augmented brain stimulation for treatment‑resistant depression
Official title: Mindfulness Engaged Neurostimulation for Depression
Run by University of California, San Diego · NCT07512284 · Data updated 2026-11-12
This trial will test whether combining fast brain stimulation (iTBS) with a digital mindfulness program helps people with treatment‑resistant depression reduce symptoms and improve thinking.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | University of California, San Diego Academic / other |
| Locations | 1 site (San Diego, California) |
| Status | Recruiting |
| Started | May 1, 2026 |
| Main results expected | April 30, 2029 |
| Study ends | April 30, 2029 |
| Registry record updated | May 6, 2026 |
| Trial ID | NCT07512284 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with a DSM‑5 major depressive episode who have failed at least one adequate antidepressant trial, have a MADRS score >19, and can provide informed consent are the intended participants.
✕Probably not a fit
People with active psychosis, current suicidal behavior, a seizure disorder, unstable medical conditions, or who are pregnant or breastfeeding are unlikely to be eligible and may not receive benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase 2 randomized controlled trial compares intermittent theta burst stimulation (iTBS) plus digital mindfulness training to iTBS with an active control training in adults with treatment‑resistant major depression. The primary outcome is suppression of posterior Default Mode Network (pDMN) activity measured by electroencephalography (EEG), with secondary outcomes of cognitive performance and depressive symptom change (MADRS). Participants must have a current major depressive episode, at least one failed adequate antidepressant trial, and moderate-to-severe symptoms. Treatment sessions and outcome assessments are delivered in person at UC San Diego with participants randomized to one of two arms.
Why it matters
Potential benefit: If successful, the combined iTBS plus mindfulness approach could raise remission rates above those typically seen with rTMS alone and improve cognitive functioning in people with treatment‑resistant depression.
How similar studies have gone: rTMS and iTBS are FDA‑approved for treatment‑resistant depression with remission rates around 30%, but combining iTBS with digital mindfulness to target pDMN activity is novel and has limited prior direct evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of major depressive episode (MDE, in accordance with the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5), in the context of unipolar major depressive disorder. * At least one failed antidepressant medication trial at level 3 in the Antidepressant -Treatment History Form: Short Form (ATHF-SF) classification. * Montgomery-Åsberg Depression Rating Scale (MADRS) Score \>19 (moderate - severe depression). * No increase or initiation of new antidepressant therapy in the four weeks prior to screening. * Demonstrated capacity to give informed consent. Exclusion Criteria: * Inability to provide informed consent. * Medically unstable patients. * Concomitant neurological disorder or a history of a seizure disorder. * Exhibiting current suicidal behavior rating on the Columbia Suicide Severity Rating Scale (C-SSRS) * Patients who are pregnant or breastfeeding. * Any psychotic disorder or current active psychotic symptoms. * Patients who have intracranial implants, other medical device or condition deemed unsafe for TMS. * Contraindication to MRI scanning.
Where it's running
-
UC San Diego Health Psychiatry
San Diego, California, United States Recruiting
Study contacts
- Study coordinator: Jyoti Mishra, PhD
- Email: braine@ucsd.edu
- Phone: 858-232-2855
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Metformin added to antidepressants for depression with obesity in Pakistani adults
This study tests whether adding metformin to antidepressant therapy helps reduce depressive symptoms and BMI in adults with depression and overweight/obesity in Pakistan.
-
Understanding the impact of mood disorders and treatment responses
This study is trying to learn more about how people with depression and bipolar disorder respond to treatment by talking to them weekly for up to 12 weeks to improve future care and predict how well medications might work.
-
Oh Happy Day Class – Digital Connections for Depression in African Americans
A mobile app delivers six weekly depression-therapy classes to African American adults to see if it helps reduce depressive symptoms.
-
Combining psilocybin with accelerated rTMS for treatment-resistant depression
This will test whether a single psilocybin dosing session followed by a short, intensive accelerated rTMS course helps adults with treatment-resistant major depressive disorder.
-
Psychotherapy to improve brain function and reduce suicidality in older adults
This study is testing a new therapy called Engage & Connect to see if it can help older adults with depression and suicidal thoughts by improving their brain function and encouraging social connections.
-
Sleep-to-Mood in Depression: Home-based tDCS
This study tests whether home-based tDCS for adults with moderate depression helps sleep improve and whether better sleep is linked to mood improvements.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.